#Germany #Munich #Seegene #CURECA #STAgora

Seegene Unveils STAgora at ESCMID Global 2026

At the recent ESCMID Global 2026 conference held in Munich, Germany, Seegene, a prominent name in molecular diagnostics, introduced its innovative platform, STAgora. This platform enables real-time data analytics, an advancement that is expected to redefine how medical professionals analyze and respond to infectious diseases. The event, which took place from April 17 to 21, attracted a plethora of healthcare professionals, researchers, and industry stakeholders eager to witness Seegene's cutting-edge technologies.

The STAgora Experience

Within the Seegene booth, attendees were treated to an immersive experience at the STAgora™ Experience Zone. The interactive demonstration highlighted the platform's capabilities, particularly its ability to aggregate statistical data from PCR testing in real time. Visitors engaged with simulations, which showcased STAgora's user-friendly interface and sophisticated data visualization tools.

A key feature presented was the enhanced model of CURECA, Seegene’s automated PCR workflow system. This model demonstrated advancements in laboratory automation, incorporating preprocessing, nucleic acid extraction, amplification, and result processing in a modular structure. The integration of these systems aims to facilitate seamless laboratory operations while boosting efficiency in diagnosing infections.

Insights from the Conference

During the conference, Seegene’s central message focused on leveraging data from established testing infrastructures to gain deeper insights into public health trends. Young Seag Baeg, Seegene's New Business Officer, emphasized the importance of connecting PCR testing data globally in real-time to provide clearer narratives about infectious disease patterns.

"STAgora is designed to connect PCR testing data generated around the world in real time," he explained. The insights gained from this data can significantly aid in understanding health trends, informing public health strategies, and enhancing response mechanisms to emerging infections.

Attendees were particularly interested in the real-time dashboards that illustrate comparative data between single-target and syndromic PCR outputs. Notable topics of discussion included regional infection trends, pathogen-specific positivity rates, and co-infection patterns—each analysis feeding into a broader understanding of epidemiological shifts.

Engaging with Professionals

Engagement was robust throughout the event, with numerous healthcare professionals expressing their enthusiasm for the potential applications of STAgora. A clinician from a university hospital commented on the platform's intuitive design for visualizing testing data trends, expressing that such tools could be pivotal in clinical decision-making and public health surveillance.

Seegene's strategic focus appears to align closely with the growing field of syndromic PCR testing, which enhances disease detection capabilities by enabling simultaneous testing for multiple pathogens. This expanded analysis framework could revolutionize how laboratories interpret and act upon aggregated testing data in diverse settings.

Looking Ahead

The interest generated at ESCMID Global 2026 has prompted Seegene to consider pilot programs and collaborations with healthcare institutions to further assess the platform's capabilities and promote its adoption. Daniel Shin, the Executive Vice President and Chief Global Sales and Marketing Officer, stated that the company seeks to validate STAgora through partnerships with clinical and academic entities across Europe.

Furthermore, this initiative supports Seegene's overarching goal of broadening the reach of its diagnostic technologies, which were notably instrumental during the COVID-19 pandemic, supplying millions of tests worldwide.

As Seegene continues to expand its offerings, including the technological ecosystems surrounding STAgora and CURECA, the implications for improved global health management and the rapid response to infectious disease outbreaks are immense. By forging strong connections with laboratories and healthcare systems, Seegene aims to enhance the landscape of molecular diagnostics for years to come.